Association of Renal Function and Statin Therapy with Lipoprotein(a) in Patients with Type 2 Diabetes

Overview

Journal J Atheroscler Thromb

Date 2023 Aug 9

PMID 37558461

Authors

Chika Hiraishi

Sadako Matsui

Takai Kojima

Ryo Sato

Kiyotaka Ando

Kei Fujimoto

Hiroshi Yoshida

Affiliations

Soon will be listed here.

Abstract

Aim: A high level of serum lipoprotein(a) [Lp(a)] is associated with kidney disease development in patients with type 2 diabetes (T2DM). Recent studies have suggested that statins may affect serum levels of Lp(a). However, the statin effect is not well-defined in patients with T2DM with kidney dysfunction. This retrospective study aimed to investigate the relevance of kidney dysfunction and statin therapy to Lp(a) in patients with T2DM.

Methods: Japanese patients with T2DM (n=149, 96 men and 53 women) were divided into two groups: statin users (n=79) and non-statin users (n=70). Multiple logistic regression analyses were performed with Lp(a) as the objective variable and estimated glomerular filtration rate (eGFR), hemoglobin A1c, age, gender, and body mass index as the explanatory variables.

Results: Lp(a) serum levels were higher in statin users than in non-statin users (P=0.022). Multivariate regression analysis results showed an inverse correlation of eGFR to log Lp(a) in all patients (P=0.009) and in non-statin users (P=0.025), but not in statin users. In a multiple logistic regression analysis for median Lp(a), there was an inverse association between eGFR and Lp(a) level (odds ratio, 0.965; 95% confidence interval, 0.935-0.997; P=0.030) in non-statin users as well as in all participants, but not in statin users.

Conclusions: The present study suggests that a high Lp(a) level in patients with T2DM, except in statin users, is significantly associated with decreased eGFR, indicating that the increased Lp(a) levels under statin therapy might diminish the relationship between Lp(a) and eGFR.

Citing Articles

Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study.

Wang Z, Tang J, Shi Q, Fang L, Liu N, Zhang J Ann Med. 2025; 57(1):2454975.

PMID: 39898960 PMC: 11792142. DOI: 10.1080/07853890.2025.2454975.

References

Willeit P, Ridker P, Nestel P, Simes J, Tonkin A, Pedersen T . Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018; 392(10155):1311-1320. DOI: 10.1016/S0140-6736(18)31652-0. View

Emdin C, Khera A, Natarajan P, Klarin D, Won H, Peloso G . Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. J Am Coll Cardiol. 2016; 68(25):2761-2772. PMC: 5328146. DOI: 10.1016/j.jacc.2016.10.033. View

Yun J, Lim T, Cha S, Ahn Y, Song K, Choi J . Lipoprotein(a) predicts the development of diabetic retinopathy in people with type 2 diabetes mellitus. J Clin Lipidol. 2016; 10(2):426-33. DOI: 10.1016/j.jacl.2015.12.030. View

Kronenberg F, Utermann G . Lipoprotein(a): resurrected by genetics. J Intern Med. 2012; 273(1):6-30. DOI: 10.1111/j.1365-2796.2012.02592.x. View

Ikewaki K . In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. Clin Exp Nephrol. 2013; 18(2):261-4. DOI: 10.1007/s10157-013-0881-x. View

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J, Haffner S . Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006; 29(6):1220-6. DOI: 10.2337/dc05-2465. View

Keane W . Lipids and the kidney. Kidney Int. 1994; 46(3):910-20. DOI: 10.1038/ki.1994.349. View

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Lin J, Reilly M, Terembula K, Wilson F . Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLoS One. 2014; 9(12):e114397. PMC: 4260843. DOI: 10.1371/journal.pone.0114397. View

10.

Senba H, Furukawa S, Sakai T, Niiya T, Miyake T, Yamamoto S . Serum lipoprotein(a) levels and diabetic nephropathy among Japanese patients with type 2 diabetes mellitus. J Diabetes Complications. 2016; 30(5):923-7. DOI: 10.1016/j.jdiacomp.2016.02.006. View

11.

Tsimikas S, Gordts P, Nora C, Yeang C, Witztum J . Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019; 41(24):2275-2284. DOI: 10.1093/eurheartj/ehz310. View

12.

Tada H, Yamagami K, Nishikawa T, Yoshida T, Teramoto R, Sakata K . Lipoprotein (a) and the Risk of Chronic Kidney Disease in Hospitalized Japanese Patients. Intern Med. 2020; 59(14):1705-1710. PMC: 7434553. DOI: 10.2169/internalmedicine.4503-20. View

13.

Anagnostis P, Karras S, Lambrinoudaki I, Stevenson J, Goulis D . Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options. Int J Clin Pract. 2016; 70(12):967-977. DOI: 10.1111/ijcp.12903. View

14.

Tsimikas S, Fazio S, Ferdinand K, Ginsberg H, Koschinsky M, Marcovina S . NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J Am Coll Cardiol. 2018; 71(2):177-192. PMC: 5868960. DOI: 10.1016/j.jacc.2017.11.014. View

15.

Yoshida H, Shoda T, Yanai H, Ikewaki K, Kurata H, Ito K . Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis. 2012; 226(1):161-4. DOI: 10.1016/j.atherosclerosis.2012.10.069. View

16.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. DOI: 10.1053/j.ajkd.2008.12.034. View

17.

Kearney P, Blackwell L, Collins R, Keech A, Simes J, Peto R . Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607):117-25. DOI: 10.1016/S0140-6736(08)60104-X. View

18.

Schwartz G, Ballantyne C . Existing and emerging strategies to lower Lipoprotein(a). Atherosclerosis. 2022; 349:110-122. DOI: 10.1016/j.atherosclerosis.2022.04.020. View

19.

Kostner G, Gavish D, Leopold B, Bolzano K, Weintraub M, Breslow J . HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989; 80(5):1313-9. DOI: 10.1161/01.cir.80.5.1313. View

20.

Vonbank A, Saely C, Rein P, Zanolin D, Drexel H . Lipoprotein (a), the Metabolic Syndrome and Vascular Risk in Angiographied Coronary Patients. J Clin Endocrinol Metab. 2016; 101(8):3199-203. DOI: 10.1210/jc.2016-1400. View